PMC:7205724 / 263-570 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"5","span":{"begin":68,"end":76},"obj":"Disease"},{"id":"7","span":{"begin":151,"end":159},"obj":"Disease"},{"id":"10","span":{"begin":164,"end":167},"obj":"Gene"},{"id":"11","span":{"begin":236,"end":244},"obj":"Disease"},{"id":"17","span":{"begin":270,"end":273},"obj":"Gene"},{"id":"19","span":{"begin":297,"end":305},"obj":"Species"},{"id":"20","span":{"begin":249,"end":260},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"tao:has_database_id","subj":"5","obj":"MESH:C000657245"},{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"MESH:C000657245"},{"id":"A10","pred":"tao:has_database_id","subj":"10","obj":"Gene:3569"},{"id":"A11","pred":"tao:has_database_id","subj":"11","obj":"MESH:C000657245"},{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"Gene:3569"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"Tax:9606"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"MESH:C502936"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"comes.\n• The use of corticosteroids might accelerate recovery from COVID-19.\n• No controlled clinical trials exist on the use of corticosteroids for COVID-19.\n• IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients w"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":68,"end":76},"obj":"Disease"},{"id":"T3","span":{"begin":151,"end":159},"obj":"Disease"},{"id":"T4","span":{"begin":236,"end":244},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"comes.\n• The use of corticosteroids might accelerate recovery from COVID-19.\n• No controlled clinical trials exist on the use of corticosteroids for COVID-19.\n• IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients w"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":21,"end":36},"obj":"Chemical"},{"id":"T5","span":{"begin":131,"end":146},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"comes.\n• The use of corticosteroids might accelerate recovery from COVID-19.\n• No controlled clinical trials exist on the use of corticosteroids for COVID-19.\n• IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients w"}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T2","span":{"begin":207,"end":217},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A2","pred":"meddra_id","subj":"T2","obj":"http://purl.bioontology.org/ontology/MEDDRA/10062178"}],"text":"comes.\n• The use of corticosteroids might accelerate recovery from COVID-19.\n• No controlled clinical trials exist on the use of corticosteroids for COVID-19.\n• IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients w"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T3","span":{"begin":21,"end":36},"obj":"Chemical"},{"id":"T4","span":{"begin":131,"end":146},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"comes.\n• The use of corticosteroids might accelerate recovery from COVID-19.\n• No controlled clinical trials exist on the use of corticosteroids for COVID-19.\n• IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients w"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T2","span":{"begin":68,"end":76},"obj":"Species"},{"id":"T3","span":{"begin":151,"end":159},"obj":"Species"},{"id":"T4","span":{"begin":236,"end":244},"obj":"Species"}],"attributes":[{"id":"A2","pred":"ncbi_taxonomy_id","subj":"T2","obj":"NCBItxid:2697049"},{"id":"A3","pred":"ncbi_taxonomy_id","subj":"T3","obj":"NCBItxid:2697049"},{"id":"A4","pred":"ncbi_taxonomy_id","subj":"T4","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"comes.\n• The use of corticosteroids might accelerate recovery from COVID-19.\n• No controlled clinical trials exist on the use of corticosteroids for COVID-19.\n• IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients w"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T6","span":{"begin":7,"end":77},"obj":"Sentence"},{"id":"T7","span":{"begin":78,"end":160},"obj":"Sentence"},{"id":"T8","span":{"begin":161,"end":245},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"comes.\n• The use of corticosteroids might accelerate recovery from COVID-19.\n• No controlled clinical trials exist on the use of corticosteroids for COVID-19.\n• IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients w"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"5","span":{"begin":68,"end":76},"obj":"Disease"},{"id":"7","span":{"begin":151,"end":159},"obj":"Disease"},{"id":"10","span":{"begin":164,"end":167},"obj":"Gene"},{"id":"11","span":{"begin":236,"end":244},"obj":"Disease"},{"id":"20","span":{"begin":249,"end":260},"obj":"Chemical"},{"id":"17","span":{"begin":270,"end":273},"obj":"Gene"},{"id":"19","span":{"begin":297,"end":305},"obj":"Species"}],"attributes":[{"id":"A5","pred":"pubann:denotes","subj":"5","obj":"MESH:C000657245"},{"id":"A7","pred":"pubann:denotes","subj":"7","obj":"MESH:C000657245"},{"id":"A10","pred":"pubann:denotes","subj":"10","obj":"Gene:3569"},{"id":"A11","pred":"pubann:denotes","subj":"11","obj":"MESH:C000657245"},{"id":"A20","pred":"pubann:denotes","subj":"20","obj":"MESH:C502936"},{"id":"A17","pred":"pubann:denotes","subj":"17","obj":"Gene:3569"},{"id":"A19","pred":"pubann:denotes","subj":"19","obj":"Tax:9606"}],"text":"comes.\n• The use of corticosteroids might accelerate recovery from COVID-19.\n• No controlled clinical trials exist on the use of corticosteroids for COVID-19.\n• IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients w"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T1","span":{"begin":164,"end":167},"obj":"Protein"},{"id":"T45","span":{"begin":270,"end":273},"obj":"Protein"}],"attributes":[{"id":"A1","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A2","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A3","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A4","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A5","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A6","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A7","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A8","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A9","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A10","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A11","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A12","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A13","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A14","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A15","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A16","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A17","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A18","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A19","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A20","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A21","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A22","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A23","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A24","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A25","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A26","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A27","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A28","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A29","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A30","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A31","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A32","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A33","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A34","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A35","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A36","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A37","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A38","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A39","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A40","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A41","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A42","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A43","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A44","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/A0S0B0"},{"id":"A45","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A46","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A47","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A48","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A49","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A50","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A51","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A52","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A53","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A54","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A55","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A56","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A57","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A58","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A59","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A60","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A61","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A62","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A63","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A64","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A65","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A66","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A67","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A68","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A69","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A70","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A71","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A72","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A73","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A74","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A75","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A76","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A77","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A78","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A79","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A80","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A81","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A82","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A83","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A84","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A85","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A86","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A87","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A88","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/A0S0B0"}],"text":"comes.\n• The use of corticosteroids might accelerate recovery from COVID-19.\n• No controlled clinical trials exist on the use of corticosteroids for COVID-19.\n• IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients w"}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T37","span":{"begin":7,"end":8},"obj":"PDT"},{"id":"T38","span":{"begin":10,"end":13},"obj":"DT"},{"id":"T39","span":{"begin":14,"end":17},"obj":"NN"},{"id":"T40","span":{"begin":18,"end":20},"obj":"IN"},{"id":"T41","span":{"begin":21,"end":36},"obj":"NNS"},{"id":"T42","span":{"begin":37,"end":42},"obj":"MD"},{"id":"T43","span":{"begin":43,"end":53},"obj":"VB"},{"id":"T44","span":{"begin":54,"end":62},"obj":"NN"},{"id":"T45","span":{"begin":63,"end":67},"obj":"IN"},{"id":"T46","span":{"begin":68,"end":76},"obj":"NN"},{"id":"T47","span":{"begin":78,"end":79},"obj":"PDT"},{"id":"T48","span":{"begin":81,"end":83},"obj":"DT"},{"id":"T49","span":{"begin":84,"end":94},"obj":"VBN"},{"id":"T50","span":{"begin":95,"end":103},"obj":"JJ"},{"id":"T51","span":{"begin":104,"end":110},"obj":"NNS"},{"id":"T52","span":{"begin":111,"end":116},"obj":"VBP"},{"id":"T53","span":{"begin":117,"end":119},"obj":"IN"},{"id":"T54","span":{"begin":120,"end":123},"obj":"DT"},{"id":"T55","span":{"begin":124,"end":127},"obj":"NN"},{"id":"T56","span":{"begin":128,"end":130},"obj":"IN"},{"id":"T57","span":{"begin":131,"end":146},"obj":"NNS"},{"id":"T58","span":{"begin":147,"end":150},"obj":"IN"},{"id":"T59","span":{"begin":151,"end":159},"obj":"NN"},{"id":"T60","span":{"begin":161,"end":162},"obj":"LS"},{"id":"T61","span":{"begin":164,"end":167},"obj":"NN"},{"id":"T62","span":{"begin":168,"end":178},"obj":"VBZ"},{"id":"T63","span":{"begin":179,"end":183},"obj":"IN"},{"id":"T64","span":{"begin":184,"end":192},"obj":"NN"},{"id":"T65","span":{"begin":192,"end":193},"obj":"-COMMA-"},{"id":"T66","span":{"begin":194,"end":205},"obj":"NN"},{"id":"T67","span":{"begin":205,"end":206},"obj":"-COMMA-"},{"id":"T68","span":{"begin":207,"end":212},"obj":"JJ"},{"id":"T69","span":{"begin":213,"end":217},"obj":"NN"},{"id":"T70","span":{"begin":217,"end":218},"obj":"-COMMA-"},{"id":"T71","span":{"begin":219,"end":222},"obj":"CC"},{"id":"T72","span":{"begin":223,"end":232},"obj":"NN"},{"id":"T73","span":{"begin":233,"end":235},"obj":"IN"},{"id":"T74","span":{"begin":236,"end":244},"obj":"NN"},{"id":"T75","span":{"begin":246,"end":247},"obj":"IN"},{"id":"T76","span":{"begin":249,"end":260},"obj":"NNP"},{"id":"T77","span":{"begin":260,"end":261},"obj":"-COMMA-"},{"id":"T78","span":{"begin":262,"end":264},"obj":"DT"},{"id":"T79","span":{"begin":265,"end":273},"obj":"NN"},{"id":"T80","span":{"begin":273,"end":274},"obj":"-COMMA-"},{"id":"T81","span":{"begin":275,"end":278},"obj":"MD"},{"id":"T82","span":{"begin":279,"end":285},"obj":"VB"},{"id":"T83","span":{"begin":286,"end":293},"obj":"NN"},{"id":"T84","span":{"begin":294,"end":296},"obj":"IN"},{"id":"T85","span":{"begin":297,"end":305},"obj":"NNS"}],"relations":[{"id":"R33","pred":"arg1Of","subj":"T39","obj":"T37"},{"id":"R34","pred":"arg1Of","subj":"T39","obj":"T38"},{"id":"R35","pred":"arg1Of","subj":"T39","obj":"T40"},{"id":"R36","pred":"arg2Of","subj":"T41","obj":"T40"},{"id":"R37","pred":"arg1Of","subj":"T39","obj":"T42"},{"id":"R38","pred":"arg2Of","subj":"T43","obj":"T42"},{"id":"R39","pred":"arg1Of","subj":"T39","obj":"T43"},{"id":"R40","pred":"arg2Of","subj":"T44","obj":"T43"},{"id":"R41","pred":"arg1Of","subj":"T44","obj":"T45"},{"id":"R42","pred":"arg2Of","subj":"T46","obj":"T45"},{"id":"R43","pred":"arg1Of","subj":"T51","obj":"T47"},{"id":"R44","pred":"arg1Of","subj":"T51","obj":"T48"},{"id":"R45","pred":"arg2Of","subj":"T51","obj":"T49"},{"id":"R46","pred":"arg1Of","subj":"T51","obj":"T50"},{"id":"R47","pred":"arg1Of","subj":"T51","obj":"T52"},{"id":"R48","pred":"arg1Of","subj":"T52","obj":"T53"},{"id":"R49","pred":"arg2Of","subj":"T55","obj":"T53"},{"id":"R50","pred":"arg1Of","subj":"T55","obj":"T54"},{"id":"R51","pred":"arg1Of","subj":"T55","obj":"T56"},{"id":"R52","pred":"arg2Of","subj":"T57","obj":"T56"},{"id":"R53","pred":"arg1Of","subj":"T55","obj":"T58"},{"id":"R54","pred":"arg2Of","subj":"T59","obj":"T58"},{"id":"R55","pred":"arg1Of","subj":"T62","obj":"T60"},{"id":"R56","pred":"arg1Of","subj":"T61","obj":"T62"},{"id":"R57","pred":"arg1Of","subj":"T62","obj":"T63"},{"id":"R58","pred":"arg2Of","subj":"T71","obj":"T63"},{"id":"R59","pred":"arg1Of","subj":"T64","obj":"T65"},{"id":"R60","pred":"arg2Of","subj":"T66","obj":"T65"},{"id":"R61","pred":"arg1Of","subj":"T65","obj":"T67"},{"id":"R62","pred":"arg2Of","subj":"T69","obj":"T67"},{"id":"R63","pred":"arg1Of","subj":"T69","obj":"T68"},{"id":"R64","pred":"arg1Of","subj":"T71","obj":"T70"},{"id":"R65","pred":"arg1Of","subj":"T67","obj":"T71"},{"id":"R66","pred":"arg2Of","subj":"T72","obj":"T71"},{"id":"R67","pred":"arg1Of","subj":"T72","obj":"T73"},{"id":"R68","pred":"arg2Of","subj":"T74","obj":"T73"},{"id":"R69","pred":"arg1Of","subj":"T82","obj":"T75"},{"id":"R70","pred":"arg1Of","subj":"T76","obj":"T77"},{"id":"R71","pred":"arg2Of","subj":"T79","obj":"T77"},{"id":"R72","pred":"arg1Of","subj":"T79","obj":"T78"},{"id":"R73","pred":"arg1Of","subj":"T82","obj":"T80"},{"id":"R74","pred":"arg1Of","subj":"T76","obj":"T81"},{"id":"R75","pred":"arg2Of","subj":"T82","obj":"T81"},{"id":"R76","pred":"arg1Of","subj":"T76","obj":"T82"},{"id":"R77","pred":"arg2Of","subj":"T83","obj":"T82"},{"id":"R78","pred":"arg1Of","subj":"T82","obj":"T84"},{"id":"R79","pred":"arg2Of","subj":"T85","obj":"T84"}],"text":"comes.\n• The use of corticosteroids might accelerate recovery from COVID-19.\n• No controlled clinical trials exist on the use of corticosteroids for COVID-19.\n• IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients w"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T2","span":{"begin":68,"end":76},"obj":"Disease"},{"id":"T3","span":{"begin":151,"end":159},"obj":"Disease"},{"id":"T4","span":{"begin":236,"end":244},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"comes.\n• The use of corticosteroids might accelerate recovery from COVID-19.\n• No controlled clinical trials exist on the use of corticosteroids for COVID-19.\n• IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients w"}

{"project":"LitCovid-sentences","denotations":[{"id":"T6","span":{"begin":7,"end":77},"obj":"Sentence"},{"id":"T7","span":{"begin":78,"end":160},"obj":"Sentence"},{"id":"T8","span":{"begin":161,"end":245},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"comes.\n• The use of corticosteroids might accelerate recovery from COVID-19.\n• No controlled clinical trials exist on the use of corticosteroids for COVID-19.\n• IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients w"}